FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3007335635> ?p ?o ?g. }

• W3007335635 endingPage "m322" @default.
• W3007335635 startingPage "m322" @default.
• W3007335635 abstract "Abstract Objective To evaluate the effectiveness and cost effectiveness of a complex intervention in primary care that aims to increase uptake of hepatitis C virus (HCV) case finding and treatment. Design Pragmatic, two armed, practice level, cluster randomised controlled trial and economic evaluation. Setting and participants 45 general practices in South West England (22 randomised to intervention and 23 to control arm). Outcome data were collected from all intervention practices and 21/23 control practices. Total number of flagged patients was 24 473 (about 5% of practice list). Intervention Electronic algorithm and flag on practice systems identifying patients with HCV risk markers (such as history of opioid dependence or HCV tests with no evidence of referral to hepatology), staff educational training in HCV, and practice posters/leaflets to increase patients’ awareness. Flagged patients were invited by letter for an HCV test (with one follow-up) and had on-screen pop-ups to encourage opportunistic testing. The intervention lasted one year, with practices recruited April to December 2016. Main outcome measures Primary outcome: uptake of HCV testing. Secondary outcomes: number of positive HCV tests and yield (proportion HCV positive); HCV treatment assessment at hepatology; cost effectiveness. Results Baseline HCV testing of flagged patients (six months before study start) was 608/13 097 (4.6%) in intervention practices and 380/11 376 (3.3%) in control practices. During the study 2071 (16%) of flagged patients in the intervention practices and 1163 (10%) in control practices were tested for HCV: overall intervention effect as an adjusted rate ratio of 1.59 (95% confidence interval 1.21 to 2.08; P<0.001). HCV antibodies were detected in 129 patients from intervention practices and 51 patients from control practices (adjusted rate ratio 2.24, 1.47 to 3.42) with weak evidence of an increase in yield (6.2% v 4.4%; adjusted risk ratio 1.40, 0.99 to 1.95). Referral and assessment increased in intervention practices compared with control practices (adjusted rate ratio 5.78, 1.6 to 21.6) with a risk difference of 1.3 per 1000 and a “number needed to help” of one extra HCV diagnosis, referral, and assessment per 792 (95% confidence interval 558 to 1883) patients flagged. The average cost of HCV case finding was £4.03 (95% confidence interval £2.27 to £5.80) per at risk patient and £3165 per additional patient assessed at hepatology. The incremental cost effectiveness ratio was £5783 per quality adjusted life year (QALY), with 93.3% probability of being below £20 000 per QALY. Conclusion HepCATT had a modest impact but is a low cost intervention that merits optimisation and implementation as part of an NHS strategy to increase HCV testing and treatment. Trial registration ISRCTN61788850." @default.
• W3007335635 created "2020-03-06" @default.
• W3007335635 creator A5000073653 @default.
• W3007335635 creator A5000583117 @default.
• W3007335635 creator A5008074980 @default.
• W3007335635 creator A5010951901 @default.
• W3007335635 creator A5023993350 @default.
• W3007335635 creator A5030708501 @default.
• W3007335635 creator A5031923231 @default.
• W3007335635 creator A5034169483 @default.
• W3007335635 creator A5036420519 @default.
• W3007335635 creator A5036570109 @default.
• W3007335635 creator A5054114945 @default.
• W3007335635 creator A5066855245 @default.
• W3007335635 creator A5069618968 @default.
• W3007335635 creator A5077131274 @default.
• W3007335635 creator A5078250568 @default.
• W3007335635 creator A5079520595 @default.
• W3007335635 creator A5085142836 @default.
• W3007335635 date "2020-02-26" @default.
• W3007335635 modified "2023-09-27" @default.
• W3007335635 title "Cost effectiveness of an intervention to increase uptake of hepatitis C virus testing and treatment (HepCATT): cluster randomised controlled trial in primary care" @default.
• W3007335635 cites W1498342390 @default.
• W3007335635 cites W166560170 @default.
• W3007335635 cites W1969350617 @default.
• W3007335635 cites W1995239249 @default.
• W3007335635 cites W2011437704 @default.
• W3007335635 cites W2054882786 @default.
• W3007335635 cites W2062663143 @default.
• W3007335635 cites W2064432456 @default.
• W3007335635 cites W2117677367 @default.
• W3007335635 cites W2133275424 @default.
• W3007335635 cites W2149638499 @default.
• W3007335635 cites W2154259558 @default.
• W3007335635 cites W2162933087 @default.
• W3007335635 cites W21944932 @default.
• W3007335635 cites W2197649852 @default.
• W3007335635 cites W2345197548 @default.
• W3007335635 cites W2395160937 @default.
• W3007335635 cites W2487319918 @default.
• W3007335635 cites W2522309098 @default.
• W3007335635 cites W2618376753 @default.
• W3007335635 cites W2744191372 @default.
• W3007335635 cites W2768722273 @default.
• W3007335635 cites W2775280810 @default.
• W3007335635 cites W2901627210 @default.
• W3007335635 cites W2909795031 @default.
• W3007335635 cites W2912219199 @default.
• W3007335635 cites W2912954134 @default.
• W3007335635 cites W2969440916 @default.
• W3007335635 cites W3008650834 @default.
• W3007335635 doi "https://doi.org/10.1136/bmj.m322" @default.
• W3007335635 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7190058" @default.
• W3007335635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32102782" @default.
• W3007335635 hasPublicationYear "2020" @default.
• W3007335635 type Work @default.
• W3007335635 sameAs 3007335635 @default.
• W3007335635 citedByCount "13" @default.
• W3007335635 countsByYear W30073356352020 @default.
• W3007335635 countsByYear W30073356352021 @default.
• W3007335635 countsByYear W30073356352022 @default.
• W3007335635 crossrefType "journal-article" @default.
• W3007335635 hasAuthorship W3007335635A5000073653 @default.
• W3007335635 hasAuthorship W3007335635A5000583117 @default.
• W3007335635 hasAuthorship W3007335635A5008074980 @default.
• W3007335635 hasAuthorship W3007335635A5010951901 @default.
• W3007335635 hasAuthorship W3007335635A5023993350 @default.
• W3007335635 hasAuthorship W3007335635A5030708501 @default.
• W3007335635 hasAuthorship W3007335635A5031923231 @default.
• W3007335635 hasAuthorship W3007335635A5034169483 @default.
• W3007335635 hasAuthorship W3007335635A5036420519 @default.
• W3007335635 hasAuthorship W3007335635A5036570109 @default.
• W3007335635 hasAuthorship W3007335635A5054114945 @default.
• W3007335635 hasAuthorship W3007335635A5066855245 @default.
• W3007335635 hasAuthorship W3007335635A5069618968 @default.
• W3007335635 hasAuthorship W3007335635A5077131274 @default.
• W3007335635 hasAuthorship W3007335635A5078250568 @default.
• W3007335635 hasAuthorship W3007335635A5079520595 @default.
• W3007335635 hasAuthorship W3007335635A5085142836 @default.
• W3007335635 hasBestOaLocation W30073356351 @default.
• W3007335635 hasConcept C112930515 @default.
• W3007335635 hasConcept C126322002 @default.
• W3007335635 hasConcept C159110408 @default.
• W3007335635 hasConcept C162324750 @default.
• W3007335635 hasConcept C164866538 @default.
• W3007335635 hasConcept C168563851 @default.
• W3007335635 hasConcept C176400912 @default.
• W3007335635 hasConcept C184356942 @default.
• W3007335635 hasConcept C187736073 @default.
• W3007335635 hasConcept C199360897 @default.
• W3007335635 hasConcept C203014093 @default.
• W3007335635 hasConcept C2522874641 @default.
• W3007335635 hasConcept C27415008 @default.
• W3007335635 hasConcept C2776135927 @default.
• W3007335635 hasConcept C2776408679 @default.
• W3007335635 hasConcept C2776455275 @default.
• W3007335635 hasConcept C2780665704 @default.
• W3007335635 hasConcept C3019080777 @default.

• next